Holger Christiansen

Leipzig, SN, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Leipzig, SN, DE 

Overview

Holger Christiansen practices practicing medicine in Leipzig, Germany.

His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ganglioneuroma, and Infantile Neutropenia.

He is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Leipzig, SN, Germany
Other Locations
Krefeld, NW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide, Methotrexate, Prednisolone, Vincristine
Study Phase: Phase 3
View 1 Less Clinical Trial

26 Total Publications

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
Journal: The Lancet. Oncology
Published: December 18, 2023

Frequently Asked Questions about Holger Christiansen

Is Holger Christiansen a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Holger Christiansen is classified as an Experienced expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Holger Christiansen participate in research or clinical trials?

Yes. Holger Christiansen has published 26 articles and abstracts on conditions like Neuroblastoma. You can view a list of Holger Christiansen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Christiansen's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile